ArticleThe Journal of biological chemistry

Novel drug discovery platform for spinocerebellar ataxia, using fluorescence technology targeting β-III-spectrin.

Robyn T Rebbeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.